title: Tumor blood flow changes induced by chemical modifiers of radiation response.
abstract: This study was designed to investigate blood flow changes induced by chemical agents that are commonly used in combination with radiation therapy. The hypoxic cell cytotoxin RSU 1069 at a dose of 100 mg/kg was shown to reduce blood flow by 80% in both SCCVII and C3H mammary tumors. Blood flow reductions of 30-40% were also observed in both tumors following administration of the radiation sensitiser pimonidazole (Ro-03-8799) at a dose of 500 mg/kg. Moreover studies in the C3H mammary tumor indicated that this effect was tumor size-dependent, being more profound and of longer duration in 500 mg than in 100 mg tumors. Blood flow decreases were also observed in the SCCVII tumor after administration of adriamycin at a dose of 15 mg/kg. Blood flow decreased by over 80% immediately after drug administration but recovered to remain 20% below control values 1 hr after drug administration. In contrast to the other agents studied, cis platinum at a dose of 2 mg/kg produced a small 20-30% increase in blood flow which persisted over the 1 hr observation period. The potential implications of these findings are discussed.
authors.affiliation: Medical Biophysics Unit, B C Cancer Research Centre, Vancouver, Canada.
authors.forename: D J
authors.initials: DJ
authors.lastname: Chaplin
authors.forename: M R
authors.initials: MR
authors.lastname: Horsman
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001783:Blood Flow Velocity / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology; D004317:Doxorubicin / Q000494:pharmacology; D051379:Mice; D008809:Mice, Inbred C3H; D008920:Misonidazole / Q000031:analogs & derivatives / Q000494:pharmacology; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000098:blood supply* / Q000503:physiopathology; D009593:Nitroimidazoles / Q000494:pharmacology; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D009593:Nitroimidazoles; D011838:Radiation-Sensitizing Agents; C033815:pimonidazole; D004317:Doxorubicin; C041712:1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol; D008920:Misonidazole; D002945:Cisplatin